

## Special Issue

# Toward a New Era in the Management of Hepatocellular Carcinoma: Novel Perspective on Therapeutic Options and Biomarkers

### Message from the Guest Editors

For over a decade, the TKI inhibitor sorafenib represented the main therapeutic option for the treatment of advanced Hepatocellular carcinoma (HCC). In the last few years, new therapies have been approved as first- and/or second-line treatments, including immunotherapeutic agents, which have also shown promising results. Despite these improvements in the pharmacological treatment of HCC, its prognosis remains poor, and the overall survival of patients remains short. In this scenario, many efforts have been and are currently directed to the identification of novel pharmacological targets that could be exploited by new candidate drugs, and the evaluation of combination therapy strategies. The identification of novel biomarkers for early diagnosis and/or as prognostic indicators of responses to treatments will also significantly improve our knowledge about HCC. This Special Issue aims to provide new insights into novel molecular targets, therapeutic options, combination therapies, and/or biomarkers that could potentially be exploited for clinical development.

---

### Guest Editors

Dr. Daniela Gabbia

Department of Pharmaceutical and Pharmacological Sciences,  
University of Padova, L. go Meneghetti 2, 35131 Padova, Italy

Dr. Sara De Martin

Department of Pharmaceutical and Pharmacological Sciences,  
University of Padova, L.go Meneghetti 2, 35131 Padova, Italy

---

### Deadline for manuscript submissions

closed (31 October 2022)



## International Journal of Molecular Sciences

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.9  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/99054](https://mdpi.com/si/99054)

*International Journal of  
Molecular Sciences*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[ijms@mdpi.com](mailto:ijms@mdpi.com)

[mdpi.com/journal/  
ijms](https://mdpi.com/journal/ijms)





# International Journal of Molecular Sciences

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.9  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
ijms](https://mdpi.com/journal/ijms)



## About the Journal

### Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

---

### Editor-in-Chief

Prof. Dr. José L. Quiles  
Department of Physiology, Institute of Nutrition and Food Technology  
"Jose Mataix", Biomedical Research Center, University of Granada,  
Avda. Conocimiento s/n, 18100 Armilla, Granada, Spain

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)